echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ​To treat autoimmune diseases, these 6 new drugs are most anticipated in the world in 2021!

    ​To treat autoimmune diseases, these 6 new drugs are most anticipated in the world in 2021!

    • Last Update: 2021-03-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    *Only for medical professionals to read the first issue of the new column, a must-see! In order to allow clinicians to better grasp the development of new drugs in the field of rheumatism in time, "Medical Rheumatism and Kidney Disease Channel" began to update the new drug column today.
    All new drug developments are here! In this issue, we will take stock of the 6 most anticipated new drugs in the world in 2021.
    Let's take a look! On February 22, foreign media Fierce Pharma and Evaluate jointly predicted and selected the 10 most anticipated innovative drugs in 2021.

    Although most of the drugs on the 2020 list achieved commercial conversion, a few did not meet expectations.

    For example, Gilead Sciences abandoned the rheumatoid arthritis JAK inhibitor Filgotinib; AstraZeneca and FibroGen may become "blockbuster" anemia drugs Roxadustat is still waiting for the new review results in March.

    At the same time, the International Antibody Society (The Antibody Society) published an analysis report on the research and development progress of new drugs in the antibody field.
    It also mentioned that 16 antibody drugs (including antibody conjugate drugs) are undergoing regulatory review in the United States or the European Union.
    There is an opportunity to receive the world's first regulatory approval in 2021.

     Most of these popular drugs are innovative biological drugs in the field of autoimmune diseases.
    Today, we will summarize these two majors to make a list of what "new drugs are coming" in the field of rheumatism and skin in 2021? Fierce Pharma: The 10 most anticipated drugs in 2021 01 Efgartigimod Company: Argenx Indication: IgG-mediated autoimmune diseases Estimated sales in 2026: $2.
    5 billion Efgartigimod is an antibody fragment under development that aims to reduce Disease immunoglobulin G (IgG) antibodies and block IgG circulation.The key Phase III ADAPT study data of Efgartigimod treatment in patients with systemic myasthenia gravis who have developed anti-acetylcholine receptor (AChR) antibodies show that patients receiving Efgartigimod achieve MG-ADL (Myasthenia Gravis Activity Score) response (first The proportion of patients who achieved improvement of 2 points or more for at least 4 consecutive weeks in the cycle was significantly higher than that of the placebo control group (67.
    7% vs 29.
    7%).

     FcRn inhibitors have few companies in the world.
    Efgartigimod is the fastest-developed product and the first product to submit a marketing application.
    It is expected to become the first approved FcRn inhibitor drug.

    Currently, Argenx is exploring a variety of autoimmune indications for Efgartigimod.

    02Deucravacitinib: Bristol-Myers Squibb (BMS) Indications: Psoriasis and other inflammatory diseases Estimated sales in 2026: US$2.
    21 billion Deucavacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor that can inhibit IL -12, IL-23 and type 1 interferon (IFN) pathways, these pathways are related to the pathogenesis of immune-mediated diseases such as psoriasis.

    The drug is the first and currently the only new, oral, selective TYK2 inhibitor in clinical research to evaluate and treat a variety of immune-mediated diseases.

     In February 2021, BMS announced that POETYK PSO-2, a key phase 3 study of Deucravacitinib in the treatment of moderate to severe plaque psoriasis, reached a common primary endpoint and multiple key secondary endpoints.

    The results showed that compared with placebo, the proportion of patients who achieved PASI 75 and skin symptoms cleared or almost cleared (sPGA of 0 or 1) was significantly increased.

     Currently, Deucravacitinib is being evaluated for the treatment of a wide range of immune-mediated diseases, including psoriasis, psoriatic arthritis, systemic lupus erythematosus and inflammatory bowel disease.

    03 Bimekizumab Company: UCB (UCB) Indication: Psoriasis Estimated sales in 2026: US$1.
    63 billion Bimekizumab is a new type of humanized monoclonal IgG1 antibody, a unique molecule with dual mechanisms of action, powerful and selective Sexually inhibit IL-17A and IL-17F.

     In the phase 3 clinical study for the treatment of moderate to severe plaque psoriasis, the efficacy of Bimekizumab has been proven to be superior to adalimumab (TNF inhibitor) and usnumab (IL-12/IL-23 inhibitor) , Skukuzumab (IL-17A inhibitor).

     Currently, the marketing application of Bimekizumab for the treatment of adult patients with moderate to severe plaque psoriasis is under review by the U.
    S.
    Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and is expected to be approved in mid-2021.

    04Tanezumab: Pfizer & Eli Lilly Indications: Osteoarthritis pain and chronic low back pain Tanezumab is a humanized IgG2k monoclonal antibody that selectively targets and blocks nerve growth factor (NGF).
    The drug is being evaluated Treatment of osteoarthritis (OA) pain and chronic low back pain (CLBP).

    When the body is injured, inflammation, or chronic pain, the level of NGF in the body will increase.

    By selectively blocking NGF, Tanezumab may help prevent pain signals from muscles, skin, or organs from reaching the spinal cord and brain.

    Tanezumab has a novel mechanism of action that is different from opioids and other analgesics (including non-steroidal anti-inflammatory drugs).

    In studies to date, Tanezumab has not yet shown a risk of addiction, misuse or dependence.

    Tanezumab was developed by Pfizer, and it has agreed with Eli Lilly to promote the global joint development and commercialization of the drug.

    In June 2017, the U.
    S.
    FDA granted Tanezumab fast track qualification for the treatment of OA pain and CLBP. It is worth mentioning that Tanezumab is the first NGF inhibitor to obtain Fast Track qualification and has the potential to become a first-line drug for the treatment of OA pain and CLBP.

    Currently, Tanezumab's Biologics License Application (BLA) for the treatment of OA pain is under review by the FDA and EMA.

    05Tralokinumab: LEO Pharma & AstraZeneca Indications: Atopic dermatitis and other inflammatory diseases.
    Tralokinumab is a fully human IgG4λ antibody that targets interleukin 13 (IL-13).
    Drug development is used to treat a variety of inflammatory diseases, including atopic dermatitis.

    IL-13 plays a key role in driving the intrinsic inflammation of atopic dermatitis.
    Tralokinumab specifically binds IL-13 with high affinity to block its interaction with the receptor and inhibit downstream IL-13 signal transduction.

    Currently, Tralokinumab's BLA for the treatment of moderate to severe atopic dermatitis is undergoing FDA and EMA review.

    If approved, Tralokinumab will break the current deadlock in the field of atopic dermatitis where there is only one biologic agent of Duplizumab.

    06Anifrolumab Company: AstraZeneca Indication: Systemic Lupus Erythematosus Anifrolumab (MEDI-546) is a fully human IgG1k antibody that specifically binds to type I interferon receptor subunit 1, blocking IFN-α, IFN-β The activity of all type I interferons including IFN-ω, thereby blocking the inflammatory pathway.

    Anifrolumab was developed by AstraZeneca.
    The BLA and MAA for the treatment of moderate to severely active, autoantibody-positive adult patients with SLE are under review by the FDA and EMA and is expected to be approved in the second half of 2021.

    Previously, the FDA has granted fast track qualification for Anifrolumab to treat SLE.

    It is estimated that 60%-80% of adult patients with lupus have an elevated type I interferon gene signature, which has been shown to be related to disease activity.

    Clinical data confirms that by targeting type I interferon receptors, Anifrolumab can reduce the disease activity of patients with lupus.

    If approved, Anifrolumab will bring a new treatment option and become the second biologic agent approved in the lupus field in 60 years (the first biologic agent is belimumab).

    Reference: [1]https:// to watch in 2021 : Yuanyi This article review: Chen Xinpeng Deputy Chief Physician Responsible Editor: Cassette Copyright Statement This article is original,
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.